Global Neuroprotection Therapeutics Markets Report 2020-2027: U. S. Market is Estimated at $15.8 Billion, While China is Forecast to Grow at 6.3% CAGR

Dublin, Sept. 14, 2020 (GLOBE NEWSWIRE) -- The "Neuroprotection Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

The global market for Neuroprotection Therapeutics estimated at US$53.6 Billion in the year 2020, is projected to reach a revised size of US$85.1 Billion by 2027, growing at a CAGR of 6.8% over the analysis period 2020-2027.

Free Radical Trapping Agents (Antioxidants), one of the segments analyzed in the report, is projected to record a 7.8% CAGR and reach US$32.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Glutamate Antagonists (Anti-Excitotoxic Agents) segment is readjusted to a revised 7.1% CAGR for the next 7-year period.

The U. S. Market is Estimated at $15.8 Billion, While China is Forecast to Grow at 6.3% CAGR

The Neuroprotection Therapeutics market in the U. S. is estimated at US$15.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$14.8 Billion by the year 2027 trailing a CAGR of 6.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.4% and 5.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Apoptosis Inhibitors Segment to Record 6.5% CAGR

In the global Apoptosis Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 6.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$6.5 Billion in the year 2020 will reach a projected size of US$10.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$9.8 Billion by the year 2027.

This report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:

• Allergan PLC

• AstraZeneca PLC

• Astrocyte Pharmaceuticals Inc.

• Biogen, Inc.

• Daiichi Sankyo Co., Ltd.

• Dr. Reddy's Laboratories Ltd.

• Eli Lilly and Company

• F. Hoffmann-La Roche AG

• Novartis International AG

• Teva Pharmaceutical Industries Ltd.

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Global Competitor Market Shares

• Neuroprotection Competitor Market Share Scenario Worldwide (in %): 2019 & 2025

• Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

IV. COMPETITION

• Total Companies Profiled: 41

For more information about this report visit https://www.researchandmarkets.com/r/9v8ja1

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900